Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Other Operating Expenses (2016 - 2025)

Fortress Biotech (FBIO) has 12 years of Other Operating Expenses data on record, last reported at $7.0 million in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 32.15% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $21.1 million, down 22.69%, while the annual FY2024 figure was $23.7 million, 30.57% down from the prior year.
  • Other Operating Expenses reached $7.0 million in Q3 2025 per FBIO's latest filing, up from $6.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $21.4 million in Q3 2021 and bottomed at -$6.1 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is $7.6 million, with a median of $7.0 million recorded in 2025.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 533.92% in 2021, then plummeted 66.29% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at -$6.1 million in 2021, then soared by 226.57% to $7.7 million in 2022, then fell by 21.17% to $6.0 million in 2023, then tumbled by 62.07% to $2.3 million in 2024, then surged by 204.58% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $7.0 million in Q3 2025, $6.0 million in Q2 2025, and $5.9 million in Q1 2025.